Ascendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Price Target of $313.52

Ascendis Pharma A/S (NASDAQ:ASND) has received an average recommendation of “Moderate Buy” from the twenty-one analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $313.52.

A number of equities analysts recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Ascendis Pharma A/S in a report on Tuesday, October 13th. KeyCorp set a $330.00 price objective on Ascendis Pharma A/S in a report on Friday. Wedbush restated an “outperform” rating and issued a $327.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, September 1st. Wall Street Zen raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Sunday, November 8th. Finally, Morgan Stanley dropped their price target on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 1st.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND traded up $8.32 during mid-day trading on Friday, reaching $275.39. 826,059 shares of the stock were exchanged, compared to its average volume of 694,460. The business’s 50 day moving average is $242.67 and its 200-day moving average is $239.83. Ascendis Pharma A/S has a 1 year low of $188.08 and a 1 year high of $282.15. The company has a market capitalization of $17.18 billion, a P/E ratio of 18.00 and a beta of 0.40. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a net margin of 73.26% and a return on equity of 44.80%. On average, equities research analysts forecast that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.

Trending Headlines about Ascendis Pharma A/S

Here are a few of the latest headlines about ASND:

• Positive Sentiment: Analyst updates lean bullish. TD Cowen raised its target to $352 and UBS lifted its target to $315, both maintaining buy ratings. Cantor Fitzgerald also raised its target to $315 with an overweight rating; RBC reaffirmed outperform at $290. These higher targets indicate continued analyst confidence in the outlook. Read More. · Read More. · Read More. · Read More.
• Positive Sentiment: Pipeline and cash-flow updates add support. European regulators issued positive opinions for TransCon CNP, with a final European Commission decision expected in Q4 2026. Management expects at least €600 million in full-year operating cash flow. Read More.
• Neutral Sentiment: Analyst views are not unanimous. Canaccord raised its target to $274 but kept a hold rating, while HC Wainwright cut its target to $335, though it retained a buy rating. Read More. · Read More.

Insider Transactions at Ascendis Pharma A/S

In other news, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the sale, the senior vice president owned 3,000 shares in the company, valued at $810,570. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 40.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds have recently modified their holdings of the business. Chicago Partners Investment Group LLC raised its position in shares of Ascendis Pharma A/S by 2.3% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 2,316 shares of the biotechnology company’s stock worth $564,000 after purchasing an additional 52 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 69 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Ascendis Pharma A/S by 48.4% in the 3rd quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 91 shares during the last quarter. ProShare Advisors LLC boosted its position in Ascendis Pharma A/S by 5.6% during the 3rd quarter. ProShare Advisors LLC now owns 2,134 shares of the biotechnology company’s stock valued at $486,000 after purchasing an additional 113 shares during the period. Finally, AlphaCentric Advisors LLC boosted its position in Ascendis Pharma A/S by 2.6% during the 3rd quarter. AlphaCentric Advisors LLC now owns 4,706 shares of the biotechnology company’s stock valued at $1,072,000 after purchasing an additional 121 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.